Intas Pharmaceuticals
Intas Pharmaceuticals is a vertically integrated global pharmaceutical company that develops, manufactures, and markets formulations.
Intas Pharmaceuticals is a vertically integrated global pharmaceutical company that develops, manufactures, and markets formulations.
Accord BioPharma receives FDA approval for **ENNUMO™ (pegfilgrastim-pccg)**, its second biosimilar version of **pegfilgrastim**, a drug used to stimulate white blood cell production in cancer patients. The approval expands Accord’s oncology portfolio under its U.S. specialty division, part of Intas Pharmaceuticals. ENNUMO™ competes with **NEULASTA® (pegfilgrastim)**, a branded treatment for chemotherapy-induced neutropenia.
Jul 2026PR NewswireNews article
The U.S. Food and Drug Administration (FDA) sends a warning letter to **Intas Pharmaceuticals Limited** for producing **adulterated finished pharmaceuticals** in violation of Current Good Manufacturing Practice (CGMP) regulations. The agency cites failures that compromise drug quality and patient safety. Intas must address the violations and submit a written response within 15 business days.
Mar 2026U.S. Food and Drug AdministrationNews article
The United Nations Institute for Training and Research (UNITAR) partners with Intas Pharmaceuticals to bring the Plasma4Life initiative to India. This expansion builds on existing efforts in Argentina and Malaysia, focusing on strengthening systems for plasma-derived medicinal products (PDMPs). The collaboration aims to enhance sustainable and cost-effective patient access to these treatments in India.
Mar 2026UNITARNews article
Accord BioPharma receives FDA approval for **FILKRI™ (filgrastim-laha)**, its biosimilar version of **NEUPOGEN® (filgrastim)**. The drug supports patients undergoing chemotherapy by stimulating white blood cell production. FILKRI™ expands treatment access with a lower-cost alternative to the reference product.
Feb 2026PR NewswireNews article